View Older Stories View More Recent Stories
-
Notable Analyst Rating Changes 11/13: (GNW) (AMAT) (BRCM) Upgraded; (MRVL) (M) (BMY) Downgraded
-
Memorial Resource Development (MRD) Prices 30M Common Secondary Offering at $23/Share
-
BMO Capital Upgrades Rosetta Resources (ROSE) to Outperform
-
BMO Capital Downgrades Laredo Petroleum (LPI) to Market Perform
-
Memorial Resource Development Corp. Announces Pricing of Secondary Public Offering of Common Stock
-
BMO Capital Retains Bullish Stance on Intercept Pharmaceuticals (ICPT) Following Q3 Results, FLINT Data
-
BMO Capital Downgrades REX Energy (REXX) to Market Perform
-
Whitestone REIT Increases Unsecured Credit Facility to $500 Million
-
Notable Analyst Rating Changes 11/7: (CA) (GNC) (SPLK) Upgraded; (OXY) (ABBV) (SLXP) Downgraded
-
UPDATE: BMO Capital Downgrades Abbvie (ABBV) to Market Perform
-
Walt Disney (DIS) PT Lifted to $100 at BMO Capital Following Q4 Results
-
Balanced Intercept (ICPT) FLINT Review Will Leave Near-Term Debate, BMO Capital Says
-
The Chefs' Warehouse (CHEF) PT, Estimates Lowered at BMO Capital
-
CBS (CBS) Q3 Results 'Positive', BMO Says
-
BMO Capital Downgrades Hormel Foods (HRL) to Market Perform
-
Regulus Therapeutics (RGLS) Price Target Raised to $34 at BMO; Could Attract Interest from Big Pharma, Says Analyst
-
BMO Capital Downgrades Sapient (SAPE) to Market Perform Amid Takeover
-
BMO Capital Downgrades Tornier (TRNX) to Market Perform
-
BMO Capital Upgrades Intrepid Potash (IPI) to Market Perform
-
BMO Capital Keeps Arena Pharma (ARNA) at 'Market Perform' Following BELVIQ Combo Update
-
Facebook (FB) Results Neutral Overall, Negative vs Expectations - BMO Capital
-
BMO Capital Downgrades Parker-Hannifin (PH) to Market Perform
-
Regulus Therapeutics (RGLS) 5.29M Offering Prices at $17/Share
-
Unusual 11 Mid-Day Movers 10/28: (RCPT) (VDSI) (SANM) Higher; (IBIO) (AMKR) (DCO) Lower
-
Receptos (RCPT) PT Raised to $125 at BMO Capital on Results
-
Twitter (TWTR) Results Neutral Overall, Negative Versus Expectations - BMO Capital; PT Cut to $46
-
Vitae Pharmaceuticals Announces Exercise of Underwriters' Option to Purchase Additional Shares of Initial Public Offering
-
Regulus Therapeutics (RGLS) Reports $80M Common Stock Offering
-
Regulus Therapeutics (RGLS) Announces $80M Common Stock Offering
-
BMO Capital Starts Civitas Solutions (CIVI) at Outperform
-
Notable Analyst Rating Changes 10/24: (MXIM) (CHKP) (HAL) Upgraded; (ANF) (CAB) (AEO) Downgraded
-
BMO Capital Starts Alibaba (BABA) at Outperform
-
BMO Capital Downgrades Abercrombie & Fitch (ANF) to Market Perform
-
Streetinsider.com's Hot Lunchtime Reads 10/22: (JNJ) (BIIB) (OCN) (FL) (RGLS)
-
Regulus (RGLS) Impressive RG101 Results Could Transform HCV Treatment, BMO Capital Says
-
Notable Analyst Rating Changes 10/22: (AOL) (CHK) (TXN) Upgraded; (CDE) (KO) (CNSL) Downgraded
-
BMO Capital Downgrades Hecla Mining (HL) to Underperform
-
BMO Capital Upgrades East West Bancorp (EWBC) to Outperform
-
BMO Capital Downgrades Coeur d'Alene Mines (CDE) to Underperform
-
Apple (AAPL) Target Raised 3% at BMO Capital Following Strong Results
-
UPDATE: BMO Capital Starts Vitae Pharmaceuticals (VTAE) at Outperform
-
BMO Capital Upgrades TubeMogul, Inc (TUBE) to Outperform
-
BMO Capital Lift PT on Regeneron (REGN) 33% Following New EYLEA Data
-
Notable Mergers and Acquisitions of the Day 10/17: (WLB)/(OXF) (EXP) (CF) (HCCI)
-
BMO Capital Upgrades Atlantic Power (AT) to Market Perform
-
Tetraphase Pharma (TTPH) Prices 3.95M Common Offering at $19/Share
-
Westmoreland Coal (WLB) to Acquire Oxford Resources GP
-
BMO Capital Upgrades Bristol-Myers Squibb Co. (BMY) to Outperform
-
BMO Capital Upgrades Cullen/Frost Bankers (CFR) to Market Perform
-
Tetraphase Pharma (TTPH) to Offer $75M in Stock

